{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:46:40Z","timestamp":1794469600266,"version":"4.9.1"},"reference-count":311,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010382","name":"European Society of Endocrinology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Women make up 51% of the world's population, and the global population of postmenopausal women is growing. About 25% of these women experience debilitating menopausal symptoms. Since it is important that all health care professionals have a fundamental knowledge of managing women presenting with symptoms related to the menopause, this European Society of Endocrinology Clinical Practice Guideline was developed. It provides guidance on evaluation and optimal clinical management of women who go through the menopause in middle age, those with Premature Ovarian Insufficiency (POI), Early Menopause and those for whom hormones are not appropriate, including women with, or at high risk of, breast cancer. This guideline discusses the benefits and risks of hormone therapy administration as well as summarizing other treatments for menopausal symptoms. Further, the contentious issue of the impact of menopausal hormone therapy in the prevention of chronic disease is considered.<\/jats:p>","DOI":"10.1093\/ejendo\/lvaf206","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T23:02:05Z","timestamp":1760396525000},"page":"G49-G81","source":"Crossref","is-referenced-by-count":73,"title":["European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause"],"prefix":"10.1093","volume":"193","author":[{"given":"Mary Ann","family":"Lumsden","sequence":"first","affiliation":[{"name":"Hon Professor of Medical Education and Gynaecology, University of Glasgow , Glasgow G12 8QQ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-7580","authenticated-orcid":false,"given":"Olaf M","family":"Dekkers","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center , 2333 ZG Leiden ,","place":["The Netherlands"]},{"name":"Department of Endocrinology and Metabolism, Leiden University Medical Center , 2333 ZG Leiden ,","place":["The Netherlands"]},{"name":"Department of Clinical Epidemiology, Aarhus University , 8000 Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie S","family":"Faubion","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic, Jacksonville, Florida and Mayo Clinic Center for Women's Health , Rochester, MN 55901 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Lind\u00e9n Hirschberg","sequence":"additional","affiliation":[{"name":"Department of Women's and Children's Health, Karolinska Institutet , 171 77 Stockholm ,","place":["Sweden"]},{"name":"Department of Gynecology and Reproductive Medicine, Karolinska University Hospital , 171 76 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-8223","authenticated-orcid":false,"given":"Channa N","family":"Jayasena","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion & Reproduction, Imperial College London , London SW7 2AZ ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-2668","authenticated-orcid":false,"given":"Irene","family":"Lambrinoudaki","sequence":"additional","affiliation":[{"name":"Menopause Unit, 2nd Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieion University Hospital , Athens 115 28 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Louwers","sequence":"additional","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus Medical Center , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn V","family":"Pinkerton","sequence":"additional","affiliation":[{"name":"Professor of Obstetrics and Gynecology, Division Director Midlife Health, The University of Virginia Health System Charlottesville , Charlottesville, VA 22908 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-1265","authenticated-orcid":false,"given":"Antoan Stefan","family":"Sojat","sequence":"additional","affiliation":[{"name":"National Centre for Infertility and Endocrinology of Gender, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2617-5429","authenticated-orcid":false,"given":"Leonie","family":"van Hulsteijn","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center , 2333 ZG Leiden ,","place":["The Netherlands"]},{"name":"European Society of Endocrinology , Bristol BS32 4QW ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"1","key":"2025102112162248700_lvaf206-B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12978-022-01336-7","article-title":"A review of menopause nomenclature","volume":"19","author":"Ambikairajah","year":"2022","journal-title":"Reprod Health"},{"issue":"4","key":"2025102112162248700_lvaf206-B2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/cmt.4.4.267.272","article-title":"Executive summary: stages of reproductive aging workshop (STRAW)","volume":"4","author":"Soules","year":"2001","journal-title":"Climacteric"},{"issue":"3","key":"2025102112162248700_lvaf206-B3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ogc.2011.05.006","article-title":"Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation","volume":"38","author":"Thurston","year":"2011","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"4","key":"2025102112162248700_lvaf206-B4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025102112162248700_lvaf206-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2022.04.008","article-title":"Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society","volume":"163","author":"Lambrinoudaki","year":"2022","journal-title":"Maturitas"},{"issue":"10","key":"2025102112162248700_lvaf206-B6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/medicina55100668","article-title":"Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy","volume":"55","author":"Gava","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"2025102112162248700_lvaf206-B7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"9392","key":"2025102112162248700_lvaf206-B8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"2025102112162248700_lvaf206-B9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/13697137.2021.1945026","article-title":"Differences in patient-reported hormone therapy use for menopause symptoms by provider specialty","volume":"24","author":"McCarty","year":"2021","journal-title":"Climacteric"},{"key":"2025102112162248700_lvaf206-B10","doi-asserted-by":"publisher","first-page":"108263","DOI":"10.1016\/j.maturitas.2025.108263","article-title":"Swedish physicians\u2019 knowledge of and prescribing practices for menopausal hormone therapy: a nationwide cross-sectional survey","volume":"197","author":"G\u00f6tze Eriksson","year":"2025","journal-title":"Maturitas"},{"issue":"2","key":"2025102112162248700_lvaf206-B11","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1530\/EJE-15-0625","article-title":"ESE guidelines, why and how","volume":"173","author":"Dekkers","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025102112162248700_lvaf206-B12","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025102112162248700_lvaf206-B13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.zefq.2012.05.017","article-title":"[GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables]","volume":"106","author":"Langer","year":"2012","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"7","key":"2025102112162248700_lvaf206-B14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2025102112162248700_lvaf206-B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2025102112162248700_lvaf206-B16","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jsxm.2016.09.002","article-title":"TX-004HR improves sexual function as measured by the female sexual function index in postmenopausal women with vulvar and vaginal atrophy: the REJOICE trial","volume":"13","author":"Kingsberg","year":"2016","journal-title":"J Sex Med"},{"issue":"5","key":"2025102112162248700_lvaf206-B17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2025102112162248700_lvaf206-B18","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/SPV.0000000000001170","article-title":"The impact of local estrogen on the urogenital microbiome in genitourinary syndrome of menopause: a randomized-controlled trial","volume":"28","author":"Lillemon","year":"2022","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"2025102112162248700_lvaf206-B19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/jsm.12552","article-title":"Low dose vaginal estrogens for the treatment of vulvovaginal atrophy: a randomized, placebo-controlled trial evaluating effect of estriol, estradiol or placebo on vulvovaginal atrophy symptoms","volume":"11","author":"Bride","year":"2014","journal-title":"J Sex Med"},{"issue":"13","key":"2025102112162248700_lvaf206-B20","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"2025102112162248700_lvaf206-B21","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0002-9343(01)00647-7","article-title":"Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen\/Progestin Replacement Study (HERS)","volume":"110","author":"Cauley","year":"2001","journal-title":"Am J Med"},{"issue":"9350","key":"2025102112162248700_lvaf206-B22","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(02)12001-0","article-title":"Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial","volume":"360","author":"Cherry","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"2025102112162248700_lvaf206-B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/PL00004180","article-title":"A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"issue":"1-2","key":"2025102112162248700_lvaf206-B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.maturitas.2008.09.012","article-title":"HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial","volume":"61","author":"Komulainen","year":"2008","journal-title":"Maturitas"},{"issue":"4","key":"2025102112162248700_lvaf206-B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s001980170113","article-title":"The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone","volume":"12","author":"Lees","year":"2001","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025102112162248700_lvaf206-B26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1081\/ERC-120022314","article-title":"The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis","volume":"29","author":"Liao","year":"2003","journal-title":"Endocr Res"},{"issue":"4","key":"2025102112162248700_lvaf206-B27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ajog.2004.12.067","article-title":"The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial","volume":"192","author":"Liu","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2025102112162248700_lvaf206-B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025102112162248700_lvaf206-B29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0378-5122(00)00158-4","article-title":"Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women\u2014results of the Danish Osteoporosis Prevention Study","volume":"36","author":"Mosekilde","year":"2000","journal-title":"Maturitas"},{"issue":"7","key":"2025102112162248700_lvaf206-B30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.psyneuen.2009.02.009","article-title":"A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women","volume":"34","author":"Tierney","year":"2009","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"2025102112162248700_lvaf206-B31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.maturitas.2006.01.012","article-title":"Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]","volume":"55","author":"Veerus","year":"2006","journal-title":"Maturitas"},{"issue":"7613","key":"2025102112162248700_lvaf206-B32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/bmj.39266.425069.AD","article-title":"Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women","volume":"335","author":"Vickers","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"2025102112162248700_lvaf206-B33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/09513590.2018.1505849","article-title":"Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail","volume":"35","author":"Zhu","year":"2019","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2025102112162248700_lvaf206-B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1258\/mi.2009.009014","article-title":"A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women","volume":"15","author":"Benster","year":"2009","journal-title":"Menopause Int"},{"key":"2025102112162248700_lvaf206-B35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.psyneuen.2015.04.020","article-title":"Distinct cognitive effects of estrogen and progesterone in menopausal women","volume":"59","author":"Berent-Spillson","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"2025102112162248700_lvaf206-B36","first-page":"165","article-title":"Use of medroxyprogesterone acetate to prevent menopausal symptoms","volume":"46","author":"Bullock","year":"1975","journal-title":"Obstet Gynecol"},{"issue":"8","key":"2025102112162248700_lvaf206-B37","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/gme.0b013e318247f07a","article-title":"Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women","volume":"19","author":"Hitchcock","year":"2012","journal-title":"Menopause"},{"issue":"3","key":"2025102112162248700_lvaf206-B38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0378-5122(80)90009-2","article-title":"A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women","volume":"2","author":"Nordin","year":"1980","journal-title":"Maturitas"},{"issue":"1","key":"2025102112162248700_lvaf206-B39","doi-asserted-by":"publisher","first-page":"9082","DOI":"10.1038\/s41598-023-35826-w","article-title":"Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial","volume":"13","author":"Prior","year":"2023","journal-title":"Sci Rep"},{"issue":"13","key":"2025102112162248700_lvaf206-B40","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.1980.03310130021021","article-title":"Oral medroxyprogesterone in the treatment of postmenopausal symptoms","volume":"244","author":"Schiff","year":"1980","journal-title":"JAMA"},{"issue":"8","key":"2025102112162248700_lvaf206-B41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.psyneuen.2008.05.013","article-title":"Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women","volume":"33","author":"Sch\u00fcssler","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"2025102112162248700_lvaf206-B42","first-page":"295","article-title":"Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women","volume":"12","author":"Stephenson","year":"2008","journal-title":"Int J Pharm Compd"},{"issue":"1","key":"2025102112162248700_lvaf206-B43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00042192-200310010-00004","article-title":"Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women","volume":"10","author":"Wren","year":"2003","journal-title":"Menopause"},{"issue":"1","key":"2025102112162248700_lvaf206-B44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsxm.2019.10.007","article-title":"Scoring and interpretation of the FSFI: what can be learned from 20 years of use?","volume":"17","author":"Meston","year":"2020","journal-title":"J Sex Med"},{"issue":"3","key":"2025102112162248700_lvaf206-B45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","article-title":"A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis","volume":"104","author":"Wimalawansa","year":"1998","journal-title":"Am J Med"},{"issue":"7","key":"2025102112162248700_lvaf206-B46","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.amjmed.2024.03.007","article-title":"A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis","volume":"137","author":"Wimalawansa","year":"2024","journal-title":"Am J Med"},{"key":"2025102112162248700_lvaf206-B47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.maturitas.2023.01.012","article-title":"Frequency and type of premature or early menopause in a geographically defined American population","volume":"170","author":"Rocca","year":"2023","journal-title":"Maturitas"},{"issue":"2","key":"2025102112162248700_lvaf206-B48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/13697137.2022.2153033","article-title":"The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis","volume":"26","author":"Li","year":"2023","journal-title":"Climacteric"},{"key":"2025102112162248700_lvaf206-B49","doi-asserted-by":"publisher","first-page":"104246","DOI":"10.1016\/j.ebiom.2022.104246","article-title":"Genetic landscape of a large cohort of Primary Ovarian Insufficiency: new genes and pathways and implications for personalized medicine","volume":"84","author":"Heddar","year":"2022","journal-title":"EBioMedicine"},{"key":"2025102112162248700_lvaf206-B50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.maturitas.2020.11.004","article-title":"Premature ovarian insufficiency: a toolkit for the primary care physician","volume":"147","author":"Lambrinoudaki","year":"2021","journal-title":"Maturitas"},{"issue":"6","key":"2025102112162248700_lvaf206-B51","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/13697137.2024.2408922","article-title":"Evidence-based guideline: premature ovarian insufficiency(\u2020)(\u2021)","volume":"27","author":"Panay","year":"2024","journal-title":"Climacteric"},{"issue":"4","key":"2025102112162248700_lvaf206-B52","doi-asserted-by":"publisher","first-page":"hoae065","DOI":"10.1093\/hropen\/hoae065","article-title":"Evidence-based guideline: premature ovarian insufficiency()","volume":"2024","author":"Panay","year":"2024","journal-title":"Hum Reprod Open"},{"issue":"6","key":"2025102112162248700_lvaf206-B53","doi-asserted-by":"publisher","first-page":"101600","DOI":"10.1016\/j.beem.2021.101600","article-title":"Diagnosis and management of premature ovarian insufficiency","volume":"35","author":"Rahman","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2025102112162248700_lvaf206-B54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/13697137.2021.1910232","article-title":"Cardiometabolic health in premature ovarian insufficiency","volume":"24","author":"Stevenson","year":"2021","journal-title":"Climacteric"},{"issue":"2","key":"2025102112162248700_lvaf206-B55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.fertnstert.2024.11.007","article-title":"Evidence-based guideline: premature ovarian insufficiency","volume":"123","author":"Panay","year":"2025","journal-title":"Fertil Steril"},{"issue":"4","key":"2025102112162248700_lvaf206-B56","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrendo.2017.180","article-title":"Symptoms of menopause\u2014global prevalence, physiology and implications","volume":"14","author":"Monteleone","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2025102112162248700_lvaf206-B57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/humupd\/dmac045","article-title":"Anti-M\u00fcllerian hormone for the diagnosis and prediction of menopause: a systematic review","volume":"29","author":"Nelson","year":"2023","journal-title":"Hum Reprod Update"},{"issue":"2","key":"2025102112162248700_lvaf206-B58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12020-018-1746-6","article-title":"Association between age at menopause and fracture risk: a systematic review and meta-analysis","volume":"63","author":"Anagnostis","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"2025102112162248700_lvaf206-B59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2047487314556004","article-title":"Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis","volume":"23","author":"Roeters van Lennep","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2025102112162248700_lvaf206-B60","doi-asserted-by":"publisher","first-page":"107792","DOI":"10.1016\/j.maturitas.2023.107792","article-title":"Early menopause and premature ovarian insufficiency are associated with increased risk of dementia: a systematic review and meta-analysis of observational studies","volume":"176","author":"Karamitrou","year":"2023","journal-title":"Maturitas"},{"issue":"1","key":"2025102112162248700_lvaf206-B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00737-022-01289-7","article-title":"The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency: a systematic review and meta-analysis","volume":"26","author":"Xi","year":"2023","journal-title":"Arch Womens Ment Health"},{"key":"2025102112162248700_lvaf206-B62","doi-asserted-by":"publisher","first-page":"107994","DOI":"10.1016\/j.maturitas.2024.107994","article-title":"Sexual function in women with premature ovarian insufficiency (POI): systematic review and meta-analysis","volume":"184","author":"van Zwol-Janssens","year":"2024","journal-title":"Maturitas"},{"issue":"7","key":"2025102112162248700_lvaf206-B63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"7","key":"2025102112162248700_lvaf206-B64","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1471-0528.2012.03324.x","article-title":"Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women","volume":"119","author":"Svejme","year":"2012","journal-title":"BJOG"},{"issue":"5","key":"2025102112162248700_lvaf206-B65","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE guideline: management of women with premature ovarian insufficiency","volume":"31","author":"Webber","year":"2016","journal-title":"Hum Reprod"},{"issue":"9","key":"2025102112162248700_lvaf206-B66","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.mayocp.2023.05.027","article-title":"Functional hypothalamic amenorrhea: recognition and management of a challenging diagnosis","volume":"98","author":"Saadedine","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2025102112162248700_lvaf206-B67","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"issue":"5","key":"2025102112162248700_lvaf206-B68","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/13697137.2019.1637079","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"22","author":"Davis","year":"2019","journal-title":"Climacteric"},{"issue":"1","key":"2025102112162248700_lvaf206-B69","doi-asserted-by":"publisher","first-page":"101823","DOI":"10.1016\/j.beem.2023.101823","article-title":"Premature ovarian insufficiency, early menopause, and induced menopause","volume":"38","author":"Hamoda","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2025102112162248700_lvaf206-B70","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 nonhormone therapy position statement of the North American Menopause Society","volume":"30","author":"Shufelt CL, Brown V, Carpenter JS","year":"2023","journal-title":"Menopause"},{"issue":"3","key":"2025102112162248700_lvaf206-B71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","article-title":"Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial","volume":"13","author":"Mann","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025102112162248700_lvaf206-B72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/gme.0b013e31823fe835","article-title":"Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial","volume":"19","author":"Ayers","year":"2012","journal-title":"Menopause"},{"issue":"1","key":"2025102112162248700_lvaf206-B73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10484-005-2171-1","article-title":"A behavioral group treatment program for menopausal hot flashes: results of a pilot study","volume":"30","author":"Keefer","year":"2005","journal-title":"Appl Psychophysiol Biofeedback"},{"issue":"14","key":"2025102112162248700_lvaf206-B74","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.3390\/ijerph18147711","article-title":"Effects of group and individual culturally adapted cognitive behavioral therapy on depression and sexual satisfaction among perimenopausal women","volume":"18","author":"Khoshbooii","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"2025102112162248700_lvaf206-B75","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/gme.0b013e31826ce3ed","article-title":"Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial","volume":"20","author":"Elkins","year":"2013","journal-title":"Menopause"},{"issue":"2","key":"2025102112162248700_lvaf206-B76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/00207144.2016.1131590","article-title":"Hypnotic relaxation therapy and sexual function in PostmenopausalWomen: results of a randomized clinical trial","volume":"64","author":"Johnson","year":"2016","journal-title":"Int J Clin Exp Hypn"},{"issue":"1","key":"2025102112162248700_lvaf206-B77","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/gme.0b013e31805c08dc","article-title":"Psychoeducational interventions to alleviate hot flashes: a systematic review","volume":"15","author":"Tremblay","year":"2008","journal-title":"Menopause"},{"issue":"7","key":"2025102112162248700_lvaf206-B78","doi-asserted-by":"publisher","first-page":"CD008582","DOI":"10.1002\/14651858.CD008582.pub2","article-title":"Relaxation for perimenopausal and postmenopausal symptoms","volume":"2014","author":"Saensak","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2025102112162248700_lvaf206-B79","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/gme.0b013e318272ce80","article-title":"Effects of applied relaxation on vasomotor symptoms in postmenopausal women: a randomized controlled trial","volume":"20","author":"Lindh-\u00c5strand","year":"2013","journal-title":"Menopause"},{"issue":"5","key":"2025102112162248700_lvaf206-B80","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/AOG.0000000000000821","article-title":"Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial","volume":"125","author":"Huang","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2025102112162248700_lvaf206-B81","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/GME.0b013e31826934b6","article-title":"Paced breathing compared with usual breathing for hot flashes","volume":"20","author":"Sood","year":"2013","journal-title":"Menopause"},{"issue":"6","key":"2025102112162248700_lvaf206-B82","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/gme.0b013e318204a05c","article-title":"Mindfulness training for coping with hot flashes: results of a randomized trial","volume":"18","author":"Carmody","year":"2011","journal-title":"Menopause"},{"issue":"3","key":"2025102112162248700_lvaf206-B83","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.maturitas.2004.06.015","article-title":"Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire","volume":"50","author":"Lewis","year":"2005","journal-title":"Maturitas"},{"key":"2025102112162248700_lvaf206-B84","doi-asserted-by":"publisher","first-page":"863905","DOI":"10.1155\/2012\/863905","article-title":"Effectiveness of yoga for menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials","volume":"2012","author":"Cramer","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"issue":"9","key":"2025102112162248700_lvaf206-B85","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/gme.0b013e318248ea16","article-title":"Effect of aromatherapy massage on menopausal symptoms: a randomized placebo-controlled clinical trial","volume":"19","author":"Darsareh","year":"2012","journal-title":"Menopause"},{"key":"2025102112162248700_lvaf206-B86","doi-asserted-by":"publisher","first-page":"0","DOI":"10.17795\/zjrms970","article-title":"Comparison of the efficacy of massage and aromatherapy massage with Geranium on depression in postmenopausal women: a clinical trial","volume":"17","author":"Rafsanjani","year":"2015","journal-title":"J Res Med Sci"},{"issue":"9","key":"2025102112162248700_lvaf206-B87","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jcma.2016.01.020","article-title":"Effect of lavender aromatherapy on menopause hot flushing: a crossover randomized clinical trial","volume":"79","author":"Kazemzadeh","year":"2016","journal-title":"J Chin Med Assoc"},{"issue":"3","key":"2025102112162248700_lvaf206-B88","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ctim.2013.03.007","article-title":"The effect of aromatherapy massage on the psychological symptoms of postmenopausal Iranian women","volume":"21","author":"Taavoni","year":"2013","journal-title":"Complement Ther Med"},{"issue":"6","key":"2025102112162248700_lvaf206-B89","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1080\/13697137.2022.2097865","article-title":"Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2022","journal-title":"Climacteric"},{"key":"2025102112162248700_lvaf206-B90","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jbmt.2024.03.018","article-title":"The effect of resistance training in reducing hot flushes in post-menopausal women: a meta-analysis","volume":"39","author":"Choudhry","year":"2024","journal-title":"J Bodyw Mov Ther"},{"issue":"9","key":"2025102112162248700_lvaf206-B91","doi-asserted-by":"publisher","first-page":"CD007244","DOI":"10.1002\/14651858.CD007244.pub2","article-title":"Black cohosh (Cimicifuga spp.) for menopausal symptoms","volume":"2012","author":"Leach","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6927","key":"2025102112162248700_lvaf206-B92","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/bmj.308.6927.501","article-title":"Effect of oral gamolenic acid from evening primrose oil on menopausal flushing","volume":"308","author":"Chenoy","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"2025102112162248700_lvaf206-B93","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00404-013-2852-6","article-title":"The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial","volume":"288","author":"Farzaneh","year":"2013","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"2025102112162248700_lvaf206-B94","doi-asserted-by":"publisher","first-page":"CD001395","DOI":"10.1002\/14651858.CD001395.pub4","article-title":"Phytoestrogens for menopausal vasomotor symptoms","volume":"2013","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025102112162248700_lvaf206-B95","doi-asserted-by":"publisher","first-page":"2515690X19829380","DOI":"10.1177\/2515690X19829380","article-title":"Complementary and alternative medicine for menopause","volume":"24","author":"Johnson","year":"2019","journal-title":"J Evid Based Integr Med"},{"issue":"1","key":"2025102112162248700_lvaf206-B96","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0002-9378(82)90402-1","article-title":"Prevalence of oligomenorrhea and amenorrhea in a college population","volume":"144","author":"Bachmann","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2025102112162248700_lvaf206-B97","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1471-0528.1992.tb13763.x","article-title":"Secondary amenorrhoea: prevalence and medical contact\u2014a cross-sectional study from a Danish county","volume":"99","author":"M\u00fcnster","year":"1992","journal-title":"Br J Obstet Gynaecol"},{"issue":"5","key":"2025102112162248700_lvaf206-B98","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2025102112162248700_lvaf206-B99","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2265.1995.tb01894.x","article-title":"The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey","volume":"43","author":"Vanderpump","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025102112162248700_lvaf206-B100","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2213-8587(23)00005-0","article-title":"Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis","volume":"11","author":"Wiersinga","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025102112162248700_lvaf206-B101","volume-title":"StatPearls [Internet]","author":"Yatavelli","year":"2025"},{"issue":"4","key":"2025102112162248700_lvaf206-B102","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/jhrs.JHRS_95_18","article-title":"The prevalence of polycystic ovary syndrome: a brief systematic review","volume":"13","author":"Deswal","year":"2020","journal-title":"J Hum Reprod Sci"},{"issue":"3","key":"2025102112162248700_lvaf206-B103","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/ncpendmet0734","article-title":"Prevalence and diagnosis of nonclassical congenital adrenal hyperplasia","volume":"4","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"6","key":"2025102112162248700_lvaf206-B104","first-page":"1064","article-title":"Obstructive sleep apnea: women's perspective","volume":"3","author":"Jehan","year":"2016","journal-title":"J Sleep Med Disord"},{"issue":"2","key":"2025102112162248700_lvaf206-B105","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.16481","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"2025102112162248700_lvaf206-B106","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025102112162248700_lvaf206-B107","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/cen.14828","article-title":"The prevalence of acromegaly is higher than previously reported: changes over a three-decade period","volume":"97","author":"Aagaard","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2025102112162248700_lvaf206-B108","doi-asserted-by":"publisher","first-page":"bvae084","DOI":"10.1210\/jendso\/bvae084","article-title":"Medullary thyroid cancer: epidemiology and characteristics according to data from the Marne-Ardennes register 1975\u20132018","volume":"8","author":"Caill\u00e9","year":"2024","journal-title":"J Endocr Soc"},{"issue":"8","key":"2025102112162248700_lvaf206-B109","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/1097-0142(20011015)92:8&lt;2204::AID-CNCR1564&gt;3.0.CO;2-R","article-title":"Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden","volume":"92","author":"Hemminki","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"2025102112162248700_lvaf206-B110","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/ajcn\/nqy342","article-title":"Prevalence of eating disorders over the 2000\u20132018 period: a systematic literature review","volume":"109","author":"Galmiche","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"2025102112162248700_lvaf206-B111","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/IJWH.S165474","article-title":"Asherman's syndrome: current perspectives on diagnosis and management","volume":"11","author":"Dreisler","year":"2019","journal-title":"Int J Womens Health"},{"issue":"2","key":"2025102112162248700_lvaf206-B112","first-page":"101","article-title":"Common herbal dietary supplement-drug interactions","volume":"96","author":"Asher","year":"2017","journal-title":"Am Fam Physician"},{"issue":"5","key":"2025102112162248700_lvaf206-B113","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3109\/13697137.2014.929651","article-title":"A practitioner's toolkit for managing the menopause","volume":"17","author":"Jane","year":"2014","journal-title":"Climacteric"},{"issue":"5","key":"2025102112162248700_lvaf206-B114","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/13697137.2016.1222483","article-title":"The NICE guideline\u2014menopause: diagnosis and management","volume":"19","author":"Lumsden","year":"2016","journal-title":"Climacteric"},{"issue":"2","key":"2025102112162248700_lvaf206-B115","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"2016 IMS recommendations on women's midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"issue":"5","key":"2025102112162248700_lvaf206-B116","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMcp1714787","article-title":"Hormone therapy for postmenopausal women","volume":"382","author":"Pinkerton","year":"2020","journal-title":"N Engl J Med"},{"key":"2025102112162248700_lvaf206-B117","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.maturitas.2021.12.001","article-title":"The essential menopause curriculum for healthcare professionals: a European Menopause and Andropause Society (EMAS) position statement","volume":"158","author":"Rees","year":"2022","journal-title":"Maturitas"},{"issue":"2","key":"2025102112162248700_lvaf206-B118","doi-asserted-by":"publisher","first-page":"69","DOI":"10.6118\/jmm.20000","article-title":"The 2020 menopausal hormone therapy guidelines","volume":"26","author":"Lee","year":"2020","journal-title":"J Menopausal Med"},{"issue":"2","key":"2025102112162248700_lvaf206-B119","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/GME.0000000000000516","article-title":"Symptom clusters among MsFLASH clinical trial participants","volume":"23","author":"Woods","year":"2016","journal-title":"Menopause"},{"issue":"6","key":"2025102112162248700_lvaf206-B120","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.mayocp.2023.02.025","article-title":"Impact of menopause symptoms on women in the workplace","volume":"98","author":"Faubion","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2025102112162248700_lvaf206-B121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40695-022-00073-y","article-title":"Disparities in reproductive aging and midlife health between black and white women: the Study of Women's Health Across the Nation (SWAN)","volume":"8","author":"Harlow","year":"2022","journal-title":"Womens Midlife Health"},{"issue":"25","key":"2025102112162248700_lvaf206-B122","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"2025102112162248700_lvaf206-B123","doi-asserted-by":"publisher","first-page":"CD000402","DOI":"10.1002\/14651858.CD000402.pub4","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia","volume":"2012","author":"Furness","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2025102112162248700_lvaf206-B124","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/cancers12082195","article-title":"Menopausal hormone therapy and risk of endometrial cancer: a systematic review","volume":"12","author":"Tempfer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025102112162248700_lvaf206-B125","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/aje\/kwu146","article-title":"Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992\u20132008","volume":"180","author":"Fournier","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2025102112162248700_lvaf206-B126","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","author":"The NAMS 2020 GSM Position Statement Editorial Panel","year":"2020","journal-title":"Menopause"},{"issue":"4","key":"2025102112162248700_lvaf206-B127","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/13697137.2016.1187123","article-title":"The impact of micronized progesterone on the endometrium: a systematic review","volume":"19","author":"Stute","year":"2016","journal-title":"Climacteric"},{"key":"2025102112162248700_lvaf206-B128","volume-title":"The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020"},{"issue":"17","key":"2025102112162248700_lvaf206-B129","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"276","author":"The Writing Group for the PEPI","year":"1996","journal-title":"JAMA"},{"issue":"4","key":"2025102112162248700_lvaf206-B130","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/GME.0000000000001480","article-title":"Endometrial safety and bleeding profile of a 17\u03b2-estradiol\/progesterone oral softgel capsule (TX-001HR)","volume":"27","author":"Mirkin","year":"2020","journal-title":"Menopause"},{"key":"2025102112162248700_lvaf206-B131","doi-asserted-by":"publisher","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"2025102112162248700_lvaf206-B132","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2025102112162248700_lvaf206-B133","doi-asserted-by":"publisher","first-page":"101561","DOI":"10.1016\/j.beem.2021.101561","article-title":"Hormone therapy regimens for managing the menopause and premature ovarian insufficiency","volume":"35","author":"Armeni","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2025102112162248700_lvaf206-B134","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/jwh.2013.4392","article-title":"Evaluation of the efficacy and safety of bazedoxifene\/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials","volume":"23","author":"Pinkerton","year":"2014","journal-title":"J Womens Health (Larchmt)"},{"issue":"2","key":"2025102112162248700_lvaf206-B135","doi-asserted-by":"publisher","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025102112162248700_lvaf206-B136","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/AOG.0b013e31828c5974","article-title":"Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial","volume":"121","author":"Pinkerton","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2025102112162248700_lvaf206-B137","doi-asserted-by":"publisher","first-page":"CD002978","DOI":"10.1002\/14651858.CD002978.pub2","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"2004","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2025102112162248700_lvaf206-B138","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10549-024-07307-9","article-title":"Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis","volume":"206","author":"Chlebowski","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2025102112162248700_lvaf206-B139","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.maturitas.2016.06.001","article-title":"Revised global consensus statement on menopausal hormone therapy","volume":"91","author":"de Villiers","year":"2016","journal-title":"Maturitas"},{"issue":"7","key":"2025102112162248700_lvaf206-B140","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: for whom, what, when, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"2025102112162248700_lvaf206-B141","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12905-023-02319-x","article-title":"Chronic conditions in women: the development of a National Institutes of health framework","volume":"23","author":"Temkin","year":"2023","journal-title":"BMC Womens Health"},{"issue":"1","key":"2025102112162248700_lvaf206-B142","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1530\/EJE-18-0602","article-title":"Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis","volume":"180","author":"Anagnostis","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025102112162248700_lvaf206-B143","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/GME.0b013e31827d38a5","article-title":"Impact of the severity of vasomotor symptoms on health status, resource use, and productivity","volume":"20","author":"Whiteley","year":"2013","journal-title":"Menopause"},{"issue":"6","key":"2025102112162248700_lvaf206-B144","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/gme.0b013e3182014849","article-title":"Vasomotor symptoms and cardiovascular events in postmenopausal women","volume":"18","author":"Szmuilowicz","year":"2011","journal-title":"Menopause"},{"issue":"4","key":"2025102112162248700_lvaf206-B145","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ogc.2018.07.006","article-title":"Cardiovascular implications of the menopause transition: endogenous sex hormones and vasomotor symptoms","volume":"45","author":"El Khoudary","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"9614","key":"2025102112162248700_lvaf206-B146","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(08)60346-3","article-title":"Menopause","volume":"371","author":"Nelson","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"2025102112162248700_lvaf206-B147","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of The North American Menopause Society","volume":"24","author":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause"},{"issue":"1","key":"2025102112162248700_lvaf206-B148","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1471-0528.2011.03166.x","article-title":"Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54\u201365","volume":"119","author":"Hunter","year":"2012","journal-title":"BJOG"},{"issue":"1","key":"2025102112162248700_lvaf206-B149","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1472-6874-12-44","article-title":"Variability of bothersome menopausal symptoms over time\u2014a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT)","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Womens Health"},{"issue":"9","key":"2025102112162248700_lvaf206-B150","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s11606-008-0655-4","article-title":"Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis","volume":"23","author":"Politi","year":"2008","journal-title":"J Gen Intern Med"},{"issue":"12","key":"2025102112162248700_lvaf206-B151","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.108.776823","article-title":"Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study","volume":"118","author":"Thurston","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"2025102112162248700_lvaf206-B152","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/GME.0000000000001231","article-title":"History of hot flashes and aortic calcification among postmenopausal women","volume":"25","author":"Thurston","year":"2018","journal-title":"Menopause"},{"issue":"2","key":"2025102112162248700_lvaf206-B153","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1210\/jc.2014-3062","article-title":"Associations of menopausal vasomotor symptoms with fracture incidence","volume":"100","author":"Crandall","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025102112162248700_lvaf206-B154","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.maturitas.2015.07.023","article-title":"Verbal memory and menopause","volume":"82","author":"Maki","year":"2015","journal-title":"Maturitas"},{"issue":"10","key":"2025102112162248700_lvaf206-B155","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1001\/jama.2017.11217","article-title":"Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials","volume":"318","author":"Manson","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"2025102112162248700_lvaf206-B156","doi-asserted-by":"publisher","first-page":"CD002229","DOI":"10.1002\/14651858.CD002229.pub4","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","volume":"2015","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2025102112162248700_lvaf206-B157","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.amjmed.2009.05.021","article-title":"Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women","volume":"122","author":"Salpeter","year":"2009","journal-title":"Am J Med"},{"key":"2025102112162248700_lvaf206-B158","doi-asserted-by":"publisher","first-page":"e6409","DOI":"10.1136\/bmj.e6409","article-title":"Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial","volume":"345","author":"Schierbeck","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"2025102112162248700_lvaf206-B159","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-8587(21)00269-2","article-title":"Management of menopause: a view towards prevention","volume":"10","author":"Lobo","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2025102112162248700_lvaf206-B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgaa764","article-title":"The menopause transition: signs, symptoms, and management options","volume":"106","author":"Santoro","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025102112162248700_lvaf206-B161","first-page":"64","article-title":"A comparison of transdermal and oral HRT for menopausal symptom control","volume":"51","author":"Akhila","year":"2006","journal-title":"Int J Fertil Womens Med"},{"issue":"2","key":"2025102112162248700_lvaf206-B162","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0029-7844(01)01419-3","article-title":"Low-dosage esterified estrogens opposed by progestin at 6-month intervals","volume":"98","author":"Ettinger","year":"2001","journal-title":"Obstet Gynecol"},{"issue":"6","key":"2025102112162248700_lvaf206-B163","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/gme.0b013e3181a53221","article-title":"Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study","volume":"16","author":"Lindh-\u00c5strand","year":"2009","journal-title":"Menopause"},{"issue":"11","key":"2025102112162248700_lvaf206-B164","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/GME.0000000000001241","article-title":"The 2017 hormone therapy position statement of the North American Menopause Society","volume":"25","author":"Pinkerton JV, Sanchez Aguirre F, Blake J","year":"2018","journal-title":"Menopause"},{"issue":"4","key":"2025102112162248700_lvaf206-B165","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3949\/ccjm.91a.23067","article-title":"Nonhormone therapies for vasomotor symptom management","volume":"91","author":"Iyer","year":"2024","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"2025102112162248700_lvaf206-B166","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/GME.0000000000002350","article-title":"Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause","volume":"31","author":"Pinkerton","year":"2024","journal-title":"Menopause"},{"issue":"3","key":"2025102112162248700_lvaf206-B167","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/13697137.2024.2334083","article-title":"Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis","volume":"27","author":"Chavez","year":"2024","journal-title":"Climacteric"},{"issue":"11","key":"2025102112162248700_lvaf206-B168","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/jsm.12665","article-title":"The impact of multimorbidity on sexual function in middle-aged and older women: beyond the single disease perspective","volume":"11","author":"Appa","year":"2014","journal-title":"J Sex Med"},{"issue":"3","key":"2025102112162248700_lvaf206-B169","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/gme.0b013e3181948dd0","article-title":"Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation","volume":"16","author":"Avis","year":"2009","journal-title":"Menopause"},{"issue":"8","key":"2025102112162248700_lvaf206-B170","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/jsm.12590","article-title":"Sexual function in the late postmenopause: a decade of follow-up in a population-based cohort of Australian women","volume":"11","author":"Lonn\u00e8e-Hoffmann","year":"2014","journal-title":"J Sex Med"},{"key":"2025102112162248700_lvaf206-B171","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.maturitas.2021.04.005","article-title":"Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide","volume":"148","author":"Hirschberg","year":"2021","journal-title":"Maturitas"},{"issue":"10","key":"2025102112162248700_lvaf206-B172","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"issue":"5","key":"2025102112162248700_lvaf206-B173","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/GME.0000000000001260","article-title":"The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey","volume":"26","author":"Nappi","year":"2019","journal-title":"Menopause"},{"issue":"5","key":"2025102112162248700_lvaf206-B174","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.gme.0000227401.98933.0b","article-title":"A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women","volume":"13","author":"Long","year":"2006","journal-title":"Menopause"},{"issue":"1_Part_2","key":"2025102112162248700_lvaf206-B175","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1743-6109.2009.01629.x","article-title":"Endocrine aspects of women's sexual function","volume":"7","author":"Wierman","year":"2010","journal-title":"J Sex Med"},{"issue":"10","key":"2025102112162248700_lvaf206-B176","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamainternmed.2017.3877","article-title":"Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS)","volume":"177","author":"Taylor","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2025102112162248700_lvaf206-B177","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40618-020-01192-x","article-title":"Hormonal profile of menopausal women receiving androgen replacement therapy: a meta-analysis","volume":"43","author":"Marina","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2025102112162248700_lvaf206-B178","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025102112162248700_lvaf206-B179","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025102112162248700_lvaf206-B180","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"issue":"6, Part 1 of 2","key":"2025102112162248700_lvaf206-B181","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"issue":"2","key":"2025102112162248700_lvaf206-B182","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s42000-024-00526-1","article-title":"Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review","volume":"23","author":"Anagnostis","year":"2024","journal-title":"Hormones (Athens)"},{"issue":"1","key":"2025102112162248700_lvaf206-B183","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/jc.2016-3270","article-title":"No increase in fractures after stopping hormone therapy: results from the women's health initiative","volume":"102","author":"Watts","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025102112162248700_lvaf206-B184","doi-asserted-by":"publisher","first-page":"CD004143","DOI":"10.1002\/14651858.CD004143.pub5","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"2025102112162248700_lvaf206-B185","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"2025102112162248700_lvaf206-B186","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","article-title":"Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women","volume":"291","author":"Banks","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"2025102112162248700_lvaf206-B187","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/GME.0000000000000694","article-title":"Effect of conjugated estrogens\/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials","volume":"23","author":"Gallagher","year":"2016","journal-title":"Menopause"},{"issue":"49","key":"2025102112162248700_lvaf206-B188","doi-asserted-by":"publisher","first-page":"e8659","DOI":"10.1097\/MD.0000000000008659","article-title":"Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis","volume":"96","author":"Peng","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2025102112162248700_lvaf206-B189","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025102112162248700_lvaf206-B190","doi-asserted-by":"publisher","first-page":"CD008536","DOI":"10.1002\/14651858.CD008536.pub3","article-title":"Short-term and long-term effects of tibolone in postmenopausal women","volume":"10","author":"Formoso","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2025102112162248700_lvaf206-B191","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025102112162248700_lvaf206-B192","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No. 141: management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"7","key":"2025102112162248700_lvaf206-B193","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/GME.0000000000000491","article-title":"NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older","volume":"22","author":"Gass","year":"2015","journal-title":"Menopause"},{"issue":"4","key":"2025102112162248700_lvaf206-B194","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1160\/TH06-10-0567","article-title":"Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration?","volume":"97","author":"Brosnan","year":"2007","journal-title":"Thromb Haemost"},{"issue":"7","key":"2025102112162248700_lvaf206-B195","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1055\/s-0037-1613608","article-title":"Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein","volume":"90","author":"Lacut","year":"2003","journal-title":"Thromb Haemost"},{"issue":"6","key":"2025102112162248700_lvaf206-B196","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/01.ATV.0000074146.36646.C8","article-title":"Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women","volume":"23","author":"Post","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2025102112162248700_lvaf206-B197","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1210\/jc.2007-2193","article-title":"A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women","volume":"93","author":"Shifren","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025102112162248700_lvaf206-B198","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"issue":"11","key":"2025102112162248700_lvaf206-B199","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1210\/jc.2015-2237","article-title":"Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis","volume":"100","author":"Mohammed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102112162248700_lvaf206-B200","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis","volume":"168","author":"Rovinski","year":"2018","journal-title":"Thromb Res"},{"issue":"4","key":"2025102112162248700_lvaf206-B201","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/13697137.2021.2022644","article-title":"The impact of micronized progesterone on cardiovascular events\u2014a systematic review","volume":"25","author":"Kaemmle","year":"2022","journal-title":"Climacteric"},{"key":"2025102112162248700_lvaf206-B202","doi-asserted-by":"publisher","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"2025102112162248700_lvaf206-B203","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0800743","article-title":"The effects of tibolone in older postmenopausal women","volume":"359","author":"Cummings","year":"2008","journal-title":"N Engl J Med"},{"issue":"22","key":"2025102112162248700_lvaf206-B204","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"key":"2025102112162248700_lvaf206-B205","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.2459\/JCM.0000000000000596","article-title":"Coronary artery disease after menopause and the role of estrogen replacement therapy","volume":"19 Suppl 1","author":"Savonitto","year":"2018","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"1","key":"2025102112162248700_lvaf206-B206","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0091-7435(91)90006-P","article-title":"Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence","volume":"20","author":"Stampfer","year":"1991","journal-title":"Prev Med"},{"issue":"9","key":"2025102112162248700_lvaf206-B207","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/GME.0000000000000450","article-title":"Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality","volume":"22","author":"Mikkola","year":"2015","journal-title":"Menopause"},{"issue":"6","key":"2025102112162248700_lvaf206-B208","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/gme.0b013e31824bb039","article-title":"A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative","volume":"19","author":"Steinkellner","year":"2012","journal-title":"Menopause"},{"key":"2025102112162248700_lvaf206-B209","doi-asserted-by":"publisher","first-page":"850815","DOI":"10.3389\/fphar.2022.850815","article-title":"The effects of menopause hormone therapy on lipid profile in postmenopausal women: a systematic review and meta-analysis","volume":"13","author":"Nie","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"2025102112162248700_lvaf206-B210","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/S0735-1097(99)00128-X","article-title":"Individual and combined effects of estrogen\/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease","volume":"33","author":"Herrington","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2025102112162248700_lvaf206-B211","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/13697137.2023.2273524","article-title":"Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis","volume":"27","author":"Bontempo","year":"2024","journal-title":"Climacteric"},{"key":"2025102112162248700_lvaf206-B212","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.maturitas.2020.03.007","article-title":"Menopause symptom management in women with dyslipidemias: an EMAS clinical guide","volume":"135","author":"Anagnostis","year":"2020","journal-title":"Maturitas"},{"key":"2025102112162248700_lvaf206-B213","doi-asserted-by":"publisher","first-page":"e1802","DOI":"10.1136\/bmj.e1802","article-title":"Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study","volume":"344","author":"Bretler","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"2025102112162248700_lvaf206-B214","doi-asserted-by":"publisher","first-page":"101576","DOI":"10.1016\/j.beem.2021.101576","article-title":"Hormone therapy and cardiovascular disease: benefits and harms","volume":"35","author":"Maas","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"2025102112162248700_lvaf206-B215","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1210\/clinem\/dgab389","article-title":"Changes in regional fat distribution and anthropometric measures across the menopause transition","volume":"106","author":"Greendale","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025102112162248700_lvaf206-B216","doi-asserted-by":"publisher","first-page":"e124865","DOI":"10.1172\/jci.insight.124865","article-title":"Changes in body composition and weight during the menopause transition","volume":"4","author":"Greendale","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"2025102112162248700_lvaf206-B217","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ijo.2008.25","article-title":"Increased visceral fat and decreased energy expenditure during the menopausal transition","volume":"32","author":"Lovejoy","year":"2008","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"2025102112162248700_lvaf206-B218","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41366-023-01266-9","article-title":"Longitudinal patterns of abdominal visceral and subcutaneous adipose tissue, total body composition, and anthropometric measures in postmenopausal women: results from the Women's Health Initiative","volume":"47","author":"Banack","year":"2023","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"2025102112162248700_lvaf206-B219","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1210\/jc.2006-1393","article-title":"Changes in body composition in women over six years at midlife: ovarian and chronological aging","volume":"92","author":"Sowers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025102112162248700_lvaf206-B220","doi-asserted-by":"publisher","first-page":"365.e1","DOI":"10.1016\/j.ajog.2019.09.051","article-title":"Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study","volume":"222","author":"Marlatt","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"2025102112162248700_lvaf206-B221","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41574-022-00708-0","article-title":"The interplay between diabetes mellitus and menopause: clinical implications","volume":"18","author":"Lambrinoudaki","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2025102112162248700_lvaf206-B222","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1210\/jc.2017-02449","article-title":"Menopausal hormone therapy is associated with reduced total and visceral adiposity: the OsteoLaus cohort","volume":"103","author":"Papadakis","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102112162248700_lvaf206-B223","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.maturitas.2016.06.020","article-title":"Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study","volume":"91","author":"Ebong","year":"2016","journal-title":"Maturitas"},{"issue":"5","key":"2025102112162248700_lvaf206-B224","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1210\/jcem.82.5.3925","article-title":"Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators","volume":"82","author":"Espeland","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025102112162248700_lvaf206-B225","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1359\/jbmr.2003.18.2.333","article-title":"Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study","volume":"18","author":"Jensen","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2025102112162248700_lvaf206-B226","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.maturitas.2017.01.016","article-title":"Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy","volume":"99","author":"Cintron","year":"2017","journal-title":"Maturitas"},{"issue":"5","key":"2025102112162248700_lvaf206-B227","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2025102112162248700_lvaf206-B228","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","article-title":"Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial","volume":"47","author":"Margolis","year":"2004","journal-title":"Diabetologia"},{"issue":"22","key":"2025102112162248700_lvaf206-B229","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1001\/jama.2017.16952","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force","volume":"318","author":"Gartlehner","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"2025102112162248700_lvaf206-B230","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/aje\/kwaa033","article-title":"Dual-outcome intention-to-treat analyses in the Women's health initiative randomized controlled hormone therapy trials","volume":"189","author":"Prentice","year":"2020","journal-title":"Am J Epidemiol"},{"issue":"5","key":"2025102112162248700_lvaf206-B231","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1365-2265.2004.02017.x","article-title":"Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women","volume":"60","author":"Godsland","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025102112162248700_lvaf206-B232","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13697137.2018.1514003","article-title":"Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review","volume":"22","author":"Coquoz","year":"2019","journal-title":"Climacteric"},{"issue":"2","key":"2025102112162248700_lvaf206-B233","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jcem.82.2.3746","article-title":"Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus","volume":"82","author":"Andersson","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025102112162248700_lvaf206-B234","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s001250050758","article-title":"Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM","volume":"40","author":"Brussaard","year":"1997","journal-title":"Diabetologia"},{"issue":"10","key":"2025102112162248700_lvaf206-B235","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.2337\/dc23-0451","article-title":"Effect of postmenopausal hormone therapy on glucose regulation in women with type 1 or type 2 diabetes: a systematic review and meta-analysis","volume":"46","author":"Speksnijder","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"2025102112162248700_lvaf206-B236","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.japh.2023.10.037","article-title":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","volume":"64","author":"Skelley","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"11","key":"2025102112162248700_lvaf206-B237","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/aje\/kwq049","article-title":"Reproductive hormones and obesity: 9 years of observation from the Study of Women's Health Across the Nation","volume":"171","author":"Sutton-Tyrrell","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"8","key":"2025102112162248700_lvaf206-B238","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jacc.2004.07.027","article-title":"Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women","volume":"44","author":"Rossi","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2025102112162248700_lvaf206-B239","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1161\/01.HYP.28.4.576","article-title":"Menopause is associated with endothelial dysfunction in women","volume":"28","author":"Taddei","year":"1996","journal-title":"Hypertension"},{"issue":"16","key":"2025102112162248700_lvaf206-B240","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jacc.2018.02.033","article-title":"Hypertension across a woman's life cycle","volume":"71","author":"Wenger","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2025102112162248700_lvaf206-B241","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","article-title":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial","volume":"275","author":"The Writing Group for the PEPI Trial","year":"1996","journal-title":"JAMA"},{"issue":"6","key":"2025102112162248700_lvaf206-B242","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/01.gme.0000184426.81190.01","article-title":"Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial","volume":"12","author":"Steiner","year":"2005","journal-title":"Menopause"},{"issue":"11","key":"2025102112162248700_lvaf206-B243","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/GME.0000000000001868","article-title":"Menopausal hormone therapy and hypertension: minimizing risk","volume":"28","author":"Mehta","year":"2021","journal-title":"Menopause"},{"issue":"5","key":"2025102112162248700_lvaf206-B244","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1378\/chest.127.5.1498","article-title":"Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease","volume":"127","author":"Nair","year":"2005","journal-title":"Chest"},{"issue":"10","key":"2025102112162248700_lvaf206-B245","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/HJH.0000000000000287","article-title":"The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials","volume":"32","author":"Shimbo","year":"2014","journal-title":"J Hypertens"},{"issue":"4","key":"2025102112162248700_lvaf206-B246","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/GME.0000000000000322","article-title":"Effects of hormone therapy on blood pressure","volume":"22","author":"Issa","year":"2015","journal-title":"Menopause"},{"issue":"10","key":"2025102112162248700_lvaf206-B247","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/GME.0000000000001828","article-title":"Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women's Health Initiative Observational Study (WHI-OS)","volume":"28","author":"Wild","year":"2021","journal-title":"Menopause"},{"issue":"7","key":"2025102112162248700_lvaf206-B248","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/GME.0000000000001067","article-title":"Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials","volume":"25","author":"Swica","year":"2018","journal-title":"Menopause"},{"issue":"8","key":"2025102112162248700_lvaf206-B249","doi-asserted-by":"publisher","first-page":"e1003731","DOI":"10.1371\/journal.pmed.1003731","article-title":"Menopausal hormone therapy and women's health: an umbrella review","volume":"18","author":"Zhang","year":"2021","journal-title":"PLoS Med"},{"issue":"17","key":"2025102112162248700_lvaf206-B250","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jama.2022.18324","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US preventive services task force","volume":"328","author":"Gartlehner","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"2025102112162248700_lvaf206-B251","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1161\/STROKEAHA.121.038659","article-title":"Oral contraceptives, hormone replacement therapy, and stroke risk","volume":"53","author":"Johansson","year":"2022","journal-title":"Stroke"},{"key":"2025102112162248700_lvaf206-B252","doi-asserted-by":"publisher","first-page":"c2519","DOI":"10.1136\/bmj.c2519","article-title":"Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study","volume":"340","author":"Renoux","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"2025102112162248700_lvaf206-B253","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1089\/154099903322643956","article-title":"Postmenopausal hormone therapy and migraine headache","volume":"12","author":"Misakian","year":"2003","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"2025102112162248700_lvaf206-B254","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1468-1331.2006.01557.x","article-title":"Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study","volume":"14","author":"Aegidius","year":"2007","journal-title":"Eur J Neurol"},{"issue":"2","key":"2025102112162248700_lvaf206-B255","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0378-5122(00)00215-2","article-title":"Course of primary headaches during hormone replacement therapy","volume":"38","author":"Nappi","year":"2001","journal-title":"Maturitas"},{"issue":"7","key":"2025102112162248700_lvaf206-B256","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.amjmed.2009.12.021","article-title":"Migraine headache and ischemic stroke risk: an updated meta-analysis","volume":"123","author":"Spector","year":"2010","journal-title":"Am J Med"},{"key":"2025102112162248700_lvaf206-B257","doi-asserted-by":"publisher","first-page":"b3914","DOI":"10.1136\/bmj.b3914","article-title":"Migraine and cardiovascular disease: systematic review and meta-analysis","volume":"339","author":"Sch\u00fcrks","year":"2009","journal-title":"BMJ"},{"issue":"7482","key":"2025102112162248700_lvaf206-B258","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/bmj.38302.504063.8F","article-title":"Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies","volume":"330","author":"Etminan","year":"2005","journal-title":"BMJ"},{"issue":"6","key":"2025102112162248700_lvaf206-B259","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/jnnp-2018-318254","article-title":"Migraine and risk of stroke","volume":"91","author":"\u00d8ie","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2025102112162248700_lvaf206-B260","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2053369117731172","article-title":"Migraine, menopause and hormone replacement therapy","volume":"24","author":"MacGregor","year":"2018","journal-title":"Post Reprod Health"},{"issue":"17","key":"2025102112162248700_lvaf206-B261","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2025102112162248700_lvaf206-B262","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/GME.0000000000002154","article-title":"The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context","volume":"30","author":"Chlebowski","year":"2023","journal-title":"Menopause"},{"issue":"10204","key":"2025102112162248700_lvaf206-B263","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"2025102112162248700_lvaf206-B264","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel","year":"2022","journal-title":"Menopause"},{"issue":"2","key":"2025102112162248700_lvaf206-B265","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09513590.2016.1248932","article-title":"Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis","volume":"33","author":"Yang","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2025102112162248700_lvaf206-B266","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/13697137.2017.1421925","article-title":"The impact of micronized progesterone on breast cancer risk: a systematic review","volume":"21","author":"Stute","year":"2018","journal-title":"Climacteric"},{"issue":"7","key":"2025102112162248700_lvaf206-B267","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/jnci\/djs014","article-title":"Changing concepts: menopausal hormone therapy and breast cancer","volume":"104","author":"Chlebowski","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2025102112162248700_lvaf206-B268","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1471-0528.2007.01520.x","article-title":"Hormone replacement therapy use and variations in the risk of breast cancer","volume":"115","author":"Opatrny","year":"2008","journal-title":"BJOG"},{"issue":"8","key":"2025102112162248700_lvaf206-B269","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/aogs.13817","article-title":"Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis","volume":"99","author":"Conz","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"6","key":"2025102112162248700_lvaf206-B270","doi-asserted-by":"publisher","first-page":"e2299","DOI":"10.1210\/clinem\/dgaa073","article-title":"Underlying breast cancer risk and menopausal hormone therapy","volume":"105","author":"Santen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025102112162248700_lvaf206-B271","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2025102112162248700_lvaf206-B272","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ijc.25314","article-title":"Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition","volume":"128","author":"Bakken","year":"2011","journal-title":"Int J Cancer"},{"issue":"1","key":"2025102112162248700_lvaf206-B273","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/aje\/kwp115","article-title":"Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause","volume":"170","author":"Prentice","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"11","key":"2025102112162248700_lvaf206-B274","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/GME.0000000000000698","article-title":"Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study","volume":"23","author":"Mikkola","year":"2016","journal-title":"Menopause"},{"issue":"9407","key":"2025102112162248700_lvaf206-B275","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"2025102112162248700_lvaf206-B276","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: the Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2025102112162248700_lvaf206-B277","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"key":"2025102112162248700_lvaf206-B278","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"2025102112162248700_lvaf206-B279","first-page":"783","article-title":"Menstrual factors in relation to breast cancer risk","volume":"7","author":"Titus-Ernstoff","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"2025102112162248700_lvaf206-B280","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/sj.bjc.6602472","article-title":"Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study","volume":"92","author":"Ewertz","year":"2005","journal-title":"Br J Cancer"},{"issue":"2","key":"2025102112162248700_lvaf206-B281","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2025102112162248700_lvaf206-B282","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1016\/j.clbc.2019.07.007","article-title":"The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis","volume":"19","author":"Pavlovi\u0107","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"2025102112162248700_lvaf206-B283","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/GME.0000000000001497","article-title":"Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial","volume":"27","author":"Hirschberg","year":"2020","journal-title":"Menopause"},{"issue":"2","key":"2025102112162248700_lvaf206-B284","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2025102112162248700_lvaf206-B285","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaoncol.2023.4508","article-title":"Vaginal estrogen therapy use and survival in females with breast cancer","volume":"10","author":"McVicker","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025102112162248700_lvaf206-B286","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","article-title":"Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer","volume":"142","author":"Agrawal","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2025102112162248700_lvaf206-B287","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","article-title":"Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks","volume":"232","author":"Beste","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"2025102112162248700_lvaf206-B288","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur J Cancer"},{"issue":"5","key":"2025102112162248700_lvaf206-B289","doi-asserted-by":"publisher","first-page":"CD008830","DOI":"10.1002\/14651858.CD008830.pub3","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2025102112162248700_lvaf206-B290","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"9980","key":"2025102112162248700_lvaf206-B291","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet"},{"issue":"30","key":"2025102112162248700_lvaf206-B292","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.23.01918","article-title":"Menopausal hormone therapy and ovarian and endometrial cancers: long-term follow-up of the women's health initiative randomized trials","volume":"42","author":"Chlebowski","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025102112162248700_lvaf206-B293","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/GME.0000000000000508","article-title":"Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis","volume":"23","author":"Pergialiotis","year":"2016","journal-title":"Menopause"},{"issue":"2","key":"2025102112162248700_lvaf206-B294","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.maturitas.2008.11.019","article-title":"Relations among menopausal symptoms, sleep disturbance and depressive symptoms in midlife","volume":"62","author":"Brown","year":"2009","journal-title":"Maturitas"},{"issue":"3","key":"2025102112162248700_lvaf206-B295","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/gme.0b013e3181cf8997","article-title":"The prevalence of depression symptoms and influencing factors among perimenopausal and postmenopausal women","volume":"17","author":"Timur","year":"2010","journal-title":"Menopause"},{"issue":"1-3","key":"2025102112162248700_lvaf206-B296","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jad.2007.01.034","article-title":"Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN)","volume":"103","author":"Bromberger","year":"2007","journal-title":"J Affect Disord"},{"issue":"5","key":"2025102112162248700_lvaf206-B297","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00737-011-0231-5","article-title":"Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging Study","volume":"14","author":"Morrison","year":"2011","journal-title":"Arch Womens Ment Health"},{"issue":"2","key":"2025102112162248700_lvaf206-B298","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/gme.0b013e3181450fc2","article-title":"Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study","volume":"15","author":"Woods","year":"2008","journal-title":"Menopause"},{"key":"2025102112162248700_lvaf206-B299","doi-asserted-by":"publisher","first-page":"115316","DOI":"10.1016\/j.psychres.2023.115316","article-title":"Pharmacological interventions and hormonal therapies for depressive symptoms in peri- and post-menopausal women: a network meta-analysis of randomized controlled trials","volume":"326","author":"Tseng","year":"2023","journal-title":"Psychiatry Res"},{"issue":"2","key":"2025102112162248700_lvaf206-B300","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamapsychiatry.2017.3998","article-title":"Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial","volume":"75","author":"Gordon","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2025102112162248700_lvaf206-B301","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsbmb.2013.06.001","article-title":"Cognition and mood in perimenopause: a systematic review and meta-analysis","volume":"142","author":"Weber","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"2025102112162248700_lvaf206-B302","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1080\/13697137.2022.2122792","article-title":"Brain fog in menopause: a health-care professional's guide for decision-making and counseling on cognition","volume":"25","author":"Maki","year":"2022","journal-title":"Climacteric"},{"issue":"6","key":"2025102112162248700_lvaf206-B303","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/psyg.12768","article-title":"The effect of hormone replacement therapy on cognitive function in healthy postmenopausal women: a meta-analysis of 23 randomized controlled trials","volume":"21","author":"Zhou","year":"2021","journal-title":"Psychogeriatrics"},{"issue":"7","key":"2025102112162248700_lvaf206-B304","doi-asserted-by":"publisher","first-page":"6566","DOI":"10.3390\/ijms24076566","article-title":"Cognitive decline in early and premature menopause","volume":"24","author":"Sochocka","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"41","key":"2025102112162248700_lvaf206-B305","doi-asserted-by":"publisher","first-page":"10332","DOI":"10.1523\/JNEUROSCI.3369-06.2006","article-title":"Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women","volume":"26","author":"Morrison","year":"2006","journal-title":"J Neurosci"},{"issue":"2","key":"2025102112162248700_lvaf206-B306","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.yhbeh.2012.05.003","article-title":"Estrogens, estrogen receptors, and female cognitive aging: the impact of timing","volume":"63","author":"Daniel","year":"2013","journal-title":"Horm Behav"},{"key":"2025102112162248700_lvaf206-B307","doi-asserted-by":"publisher","first-page":"104693","DOI":"10.1016\/j.phrs.2020.104693","article-title":"Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: a systematic review and time-response meta-analysis","volume":"155","author":"Wu","year":"2020","journal-title":"Pharmacol Res"},{"key":"2025102112162248700_lvaf206-B308","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fnins.2020.00157","article-title":"The effect of estrogen replacement therapy on Alzheimer's disease and Parkinson's disease in postmenopausal women: a meta-analysis","volume":"14","author":"Song","year":"2020","journal-title":"Front Neurosci"},{"key":"2025102112162248700_lvaf206-B309","doi-asserted-by":"publisher","first-page":"n2182","DOI":"10.1136\/bmj.n2182","article-title":"Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases","volume":"374","author":"Vinogradova","year":"2021","journal-title":"BMJ"},{"key":"2025102112162248700_lvaf206-B310","doi-asserted-by":"publisher","first-page":"e072770","DOI":"10.1136\/bmj-2022-072770","article-title":"Menopausal hormone therapy and dementia: nationwide, nested case-control study","volume":"381","author":"Pourhadi","year":"2023","journal-title":"BMJ"},{"key":"2025102112162248700_lvaf206-B311","doi-asserted-by":"publisher","first-page":"108003","DOI":"10.1016\/j.maturitas.2024.108003","article-title":"Risks and benefits of hormone therapy after menopause for cognitive decline and dementia: a conceptual review","volume":"184","author":"Rocca","year":"2024","journal-title":"Maturitas"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/G49\/64633007\/lvaf206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/G49\/64633007\/lvaf206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:16:31Z","timestamp":1761063391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/4\/G49\/8281862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":311,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf206","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,30]]}}}